Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 18/20 | 0.83 |
| ▸ | MEN1 | O00255 | 3/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.83 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.83 |
| ▸ | HBB | P68871 | 2/20 | 0.83 |
| ▸ | CASP1 | P29466 | 1/20 | 0.83 |
| ▸ | CASP7 | P55210 | 1/20 | 0.83 |
| ▸ | TP53 | P04637 | 2/20 | 0.80 |
| ▸ | GLA | P06280 | 2/20 | 0.80 |
| ▸ | HPGD | P15428 | 2/20 | 0.80 |
| ▸ | STAT6 | P42226 | 1/20 | 0.80 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.80 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.80 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.80 |
| ▸ | GMNN | O75496 | 1/20 | 0.80 |
| ▸ | LMNA | P02545 | 1/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28535745 | 1.00 | TOP1 (0.83) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Hydroxycamptothecin SCHEMBL25875 | 0.91 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL1007394 | 0.91 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Hydroxycamptothecin SCHEMBL29350707 | 0.91 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL12343943 | 0.91 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL1005975 | 0.91 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL17145878 | 0.91 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Hydroxycamptothecin SCHEMBL9384413 | 0.91 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Hydroxycamptothecin SCHEMBL29929278 | 0.91 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL24003729 | 0.90 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120152742-A | Polymer with dual therapeutic agents | 索尼集团公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-115429893-A | Drug conjugates and uses thereof | 百奥泰生物制药股份有限公司 | 2022-12-06 | — | — | CN | disclosed |
| US-7655640-B2 | Camptothecin analogs and methods of preparation thereof | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2010-02-02 | — | — | US | disclosed |
| CN-101578279-A | Amide substituted indazoles as poly (ADP ribose) polymerase (PARP) inhibitors | ANGELETTI P IST RICHERCHE BIO (IT) | 2009-11-11 | — | — | CN | disclosed |
| US-7514418-B2 | Camptothecin analogs and methods of preparation thereof | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1017399-B1 | CAMPTOTHECIN ANALOGS AND METHODS OF PREPARATION THEREOF | UNIV PITTSBURGH (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20080269169-A1 | Camptothecin analogs and methods of preparation thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-10-30 | — | — | US | disclosed |
| EP-1140948-A4 | CAMPTOTHECIN ANALOGS AND METHODS OF PREPARATION THEREOF | UNIV PITTSBURGH (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070259905-A1 | Camptothecin analogs and methods of preparation thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-08 | — | — | US | disclosed |
| US-7271159-B2 | Camptothecin analogs and methods of preparation thereof | UNIVERSITY OF PITTSBURGH (US) | 2007-09-18 | — | — | US | disclosed |
| WO-2002083694-A1 | SYNTHESIS OF SILYL CAMPTOTHECINS AND SILYL HOMOCAMPTOTHECINS | UNIVERSITY OF PITTSBURGH (US) | 2002-10-24 | — | — | WO | disclosed |
| US-6455699-B1 | SUCH AS (20S)10-HYDROXY-7-TERT-BUTYLDIMETHYLSILYL-CAMPHTOTHECIN; ANTITUMOR AGENTS; SOLUBILITY; BIOAVAILABILITY/ BIODISTRIBUTION | UNIVERSITY OF PITTSBURGH | 2002-09-24 | — | — | US | disclosed |
| CN-1352646-A | Camptothecin analogues and preparation method thereof | UNIV PITTSBURGH (US) | 2002-06-05 | — | — | CN | disclosed |
| US-6372906-B1 | REACTING CAMPTOTHECIN OR HOMOCAMPTOTHECIN WITH SILYL RADICAL PRECURSOR UNDER CONDITIONS TO GENERATE SILYL RADICAL | UNIVERSITY OF PITTSBURGH | 2002-04-16 | — | — | US | disclosed |
| EP-1140948-A1 | CAMPTOTHECIN ANALOGS AND METHODS OF PREPARATION THEREOF | UNIVERSITY OF PITTSBURGH (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6150343-A | 10-HYDROXY-7-SUBSTITUTED SILYLCAMPTOTHECIN DERIVATIVE IS USED AS ANTICARCINOGENIC AND ANTITUMOR AGENT | UNIVERSITY OF PITTSBURGH (US) | 2000-11-21 | — | — | US | disclosed |
| US-6136978-A | CYCLIZING SILYL COMPOUND WITH ARYL ISONITRILE COMPOUND TO FORM SILYL CAMPTOTHECIN DERIVATIVE | UNIVERSITY OF PITTSBURGH (US) | 2000-10-24 | — | — | US | disclosed |
| EP-1017399-A1 | CAMPTOTHECIN ANALOGS AND METHODS OF PREPARATION THEREOF | University of Pittsburgh (US) | 2000-07-12 | — | — | EP | disclosed |
| WO-2000035924-A1 | CAMPTOTHECIN ANALOGS AND METHODS OF PREPARATION THEREOF | UNIVERSITY OF PITTSBURGH (US) | 2000-06-22 | — | — | WO | disclosed |
| WO-1999009996-A1 | CAMPTOTHECIN ANALOGS AND METHODS OF PREPARATION THEREOF | UNIVERSITY OF PITTSBURGH (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259905-A1 | Camptothecin analogs and methods of preparation thereof | ADCY9, BCL9, ADCY10 | TOP1 53/4885MEN1 2019/4885KMT2A 3280/4885 |
| US-20080269169-A1 | Camptothecin analogs and methods of preparation thereof | TOP2A, TOP1, TOP2B | TOP1 2/4885MEN1 781/4885KMT2A 2922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.